Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| So, when you think about 2023 and I mentioned the fact that it was a transformational year for us, all of our data would tell us that over the course of the years we saw our volume momentum really pick up and increase, and we increased unit volume growth in 2023 relative to 2022 in a pretty substantial way, that despite the fact that we have 70% of that long-term cardiac monitoring space, I actually think we picked up another couple points of share in that marketplace |
| This peer-reviewed publication continues the long history of evidence that the Zio long-term continuous monitoring service provides high value and performance with the highest diagnostic yield and lowest likelihood of retesting across a wide range of ambulatory cardiac monitoring services |
| This fueled our performance in the fourth quarter that led to full-year revenue of $493 million or growth of 20% versus the prior year, in line with our long-range plan, exceeding the high end of our guidance range and reflecting momentum across multiple channels |
| In the fourth quarter, we continued building upon the solid execution of the first nine months of 2023 |
| We were pleased to see strong volume contributions from both new and existing accounts exiting the year |
| While nearly 70% of registration growth came from existing accounts, the fourth quarter was the second strongest quarter of new account openings in our history, setting up nicely as we move into 2024 |
| We’ve got numerous tailwinds that exist in the business, including primary care, the sleep pilot, our Know Your Rhythm pilots, asymptomatic screening, a full year of monitor, ramping international growth and CAMELOT continuing to become more and more popular in the marketplace |
| Importantly, the EU MDR is arguably one of the most stringent regulatory frameworks for product approvals globally and receipt of this certification demonstrates our commitment to providing the highest quality products and services |
| Quentin Blackford And keep in mind, Allen, as those registration volumes have improved really nicely over the course of February and have come together well, with our revenue recognition model, those devices go out |
| We believe the combination of the Zio monitor form factor with its smaller profile and high rate of patient compliance, as well as our refreshed MyZio app, has continued to contribute to an improved device return rate of approximately 0.5% thus far in our product launch cycle |
| While in the early stages, Zio monitor has also improved the patient journey, resulting in fewer calls into our customer care teams from patients |
| And as Brice pointed out earlier, it’s driving a nice improvement in the margin profile for us already here in 2024 and we’ll continue in 2025 |
| As we continue to transition all in-clinic accounts to Zio monitor throughout the first half of 2024, we are excited to see how the largest launch in the history of our company could catalyze additional momentum in the business |
| So Philippines is primarily those other back office functions and we’ve had great success getting that stood up, great success in terms of their focus on quality of work and the process excellence that they bring |
| Long-term, we are building the cardiac monitoring product and services portfolio of the future, and we are uniquely positioned to address the quintuple aim of health care within ACM |
| And importantly, we see a clear line of sight to deliver an increase of 400 basis points to 500 basis points in our adjusted EBITDA margin, a meaningful improvement in our profitability profile |
| Finally, we ended 2023 in a strong financial position with approximately $133.8 million of cash and short-term investments |
| The operational efficiencies we can drive for our customers is a clear differentiator, as we expect to have more exciting announcements on this front as we move through 2024 and beyond |
| So again, feel good about where the gross margin is progressing towards and the line of sight we have to get into that low-to-mid 70s profile that we put out there with the long range plan |
| While we believe that our next-generation Zio MCT device will further strengthen our competitive positioning in this space, we still believe that there are meaningful market share gains to be made with our Zio AT product compared to the approximate 7% penetration that we currently hold in the mobile cardiac telemetry category |
| In the MCT category, we estimate that every 10 points of share gain represents roughly $80 million to $100 million of incremental revenue to iRhythm, a significant opportunity for growth as we aim to deliver on our $1 billion revenue target in our long-range plan |
| As we continue to progress our product innovation roadmap, we have also continued to build upon our substantial body of clinical evidence with strong fourth quarter publication output in top-tier medical journals and at conferences |
| In the back half of the year, however, we anticipate an improvement in gross margin due to the majority of our business being transitioned to the new Zio monitor platform, initial ramp of automation lines to produce Zio monitor and our clinical operations team in San Francisco operating at full capacity |
| So that is quite encouraging and I think it’s a big part of how we think about continuing to expand within our existing accounts but also with new accounts |
| What I would say is the 21% and this has been growing nicely over the last several years and that penetration level continues to increase |
| All of those will be nice levers for us in the back half for gross margin and our exit rate is going to be at that 70% to north of 70% rate, which is some of the highest gross margins we’ve ever put up in companies’ history |
| We also continue to make strides in AI |
| So we’re excited with what’s in front of us and feel like we’ve got a lot of good tailwinds that we can execute against and I do think international will be another growth contributor, not only in 2024, but, yes, again in 2025 |
| I think the setup is terrific as we think about all the tailwinds that are in the business |
| As Quentin mentioned, this was driven by strong volumes from new accounts opened in the prior 12 months, continued penetration of existing accounts and reduced account churn |
| Statement |
|---|
| Additionally, we recorded an impairment charge of $11.1 million, related to the capitalized value of our San Francisco office, as a result of the continued declining commercial real estate market conditions within San Francisco |
| And then just as a quick follow-up, gross margins this quarter, I think, relative to your expectations, came in a little bit disappointing as you’re transitioning to Zio monitor and continuing to invest back into the business |
| Average selling prices during the fourth quarter were down approximately 400 basis points year-over-year and down slightly quarter-over-quarter |
| As previously discussed, we expected temporary gross margin pressure in the back half of 2023, primarily driven by costs associated with the transition from Zio XT to the new Zio monitor |
| We’ve incurred costs related to scaling and training newly onboarded clinical cardiac technicians that resulted in inefficiencies in the short-term |
| business now that we’ve anniversaried some of those challenges |
| You’re reiterating the full year, but you’re talking to some weather-related headwinds in first quarter |
| What we did see is large storm impacts in the northeast and really across the country in certain respects |
| This has resulted in a faster than anticipated transition from Zio XT and has created near-term pressure on the gross margin due to the accelerated recognition of costs of our legacy XT components |
| We did see a bit of pressure in the month of January |
| With significant accomplishments in 2023 and so many opportunities in the months and years ahead, I could not be more excited for our future at iRhythm |
| Our future has never been brighter |
| As we think about the first quarter, we did see weather-related impacts in January |
| Really, the contributing factor there was not being able to hire as fast as we were looking for |
| Looking into 2024, we couldn’t be more excited about the position that we are in |
| This accelerated transition does not yet have the benefit of automation and scale, which resulted in an increased cost per unit |
| During the first half of 2024, we anticipate continued direct and indirect costs from the transition to Zio monitor, natural inefficiencies from the implementation of automation to produce Zio monitor at scale, and the optimization of our center of excellence in San Francisco |
| Adjusted net loss in the fourth quarter was approximately $25.8 million or a loss of $0.84 per share, compared to an adjusted net loss of $17.9 million or an adjusted net loss of $0.59 per share in the fourth quarter of 2022 |
| So there’s a bit of cannibalization in there |
| Adjusted net loss for the full year 2023 was approximately $96.5 million or $3.16 per share, compared to an adjusted net loss of $84.5 million or a loss of $2.82 per share during 2022 |
Please consider a small donation if you think this website provides you with relevant information